JP4435985B2 - ＴｃＲγδＴ細胞の生産方法 - Google Patents

ＴｃＲγδＴ細胞の生産方法 Download PDF

Info

Publication number
JP4435985B2
JP4435985B2 JP2000579719A JP2000579719A JP4435985B2 JP 4435985 B2 JP4435985 B2 JP 4435985B2 JP 2000579719 A JP2000579719 A JP 2000579719A JP 2000579719 A JP2000579719 A JP 2000579719A JP 4435985 B2 JP4435985 B2 JP 4435985B2
Authority
JP
Japan
Prior art keywords
cells
present
amount
tcrγδ
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000579719A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002528115A5 (https=
JP2002528115A (ja
Inventor
ベル，ディビッド，ニコルソン
スケア，ダナ，リン
ヘッジ，フィリス，ロビン
Original Assignee
ヘモソル インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヘモソル インコーポレーテッド filed Critical ヘモソル インコーポレーテッド
Publication of JP2002528115A publication Critical patent/JP2002528115A/ja
Publication of JP2002528115A5 publication Critical patent/JP2002528115A5/ja
Application granted granted Critical
Publication of JP4435985B2 publication Critical patent/JP4435985B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/59—Lectins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
JP2000579719A 1998-11-04 1999-11-04 ＴｃＲγδＴ細胞の生産方法 Expired - Fee Related JP4435985B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10700698P 1998-11-04 1998-11-04
US60/107,006 1998-11-04
PCT/CA1999/001024 WO2000026347A1 (en) 1998-11-04 1999-11-04 Methods for the production of tcr gamma delta t cells

Publications (3)

Publication Number Publication Date
JP2002528115A JP2002528115A (ja) 2002-09-03
JP2002528115A5 JP2002528115A5 (https=) 2006-12-28
JP4435985B2 true JP4435985B2 (ja) 2010-03-24

Family

ID=22314363

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000579719A Expired - Fee Related JP4435985B2 (ja) 1998-11-04 1999-11-04 ＴｃＲγδＴ細胞の生産方法

Country Status (10)

Country Link
US (1) US6537812B1 (https=)
EP (1) EP1127107B1 (https=)
JP (1) JP4435985B2 (https=)
AT (1) ATE421573T1 (https=)
AU (1) AU759373B2 (https=)
CA (1) CA2349629C (https=)
DE (1) DE69940352D1 (https=)
ES (1) ES2319942T3 (https=)
NZ (1) NZ511760A (https=)
WO (1) WO2000026347A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE449162T1 (de) * 2000-04-03 2009-12-15 Therapure Biopharma Inc Herstellung von tcr gamma delta t-zellen
US20030157060A1 (en) * 2000-04-03 2003-08-21 Bell David N Production of tcr gamma delta t cells
EP1778836B1 (en) * 2004-08-19 2010-08-04 University College Cardiff Consultants Limited Preparation of antigen-presenting human gamma delta t cells and use in immunotherapy
CN101313061B (zh) 2005-11-18 2013-05-15 大学健康网络 扩增双阴性t细胞的方法
CA2659697A1 (en) 2006-08-01 2008-02-07 Arigen Pharmaceuticals, Inc. Method of proliferating lak cell
GB201421716D0 (en) * 2014-12-05 2015-01-21 King S College London Cell expansion procedure
KR102663157B1 (ko) 2015-06-09 2024-05-13 감마델타 테라퓨틱스 엘티디 Ｔｃｒ감마 델타 양성 ｔ 세포의 생산 방법
AU2016274633B2 (en) * 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
EP4148124A1 (en) 2015-10-30 2023-03-15 Cancer Research Technology Limited Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
GB201707048D0 (en) * 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
KR20210111746A (ko) * 2018-11-08 2021-09-13 감마델타 테라퓨틱스 리미티드 세포를 단리 및 증식하는 방법
EP4198120A4 (en) * 2020-08-14 2024-05-08 Shanghai Xinghua Bio Pharmaceutical Science & Technology Co., Ltd METHOD FOR PREPARING UNIVERSAL IMMUNE CELLS AND THEIR USE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639653A (en) * 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
US5877299A (en) * 1995-06-16 1999-03-02 Stemcell Technologies Inc. Methods for preparing enriched human hematopoietic cell preparations
CA2275141A1 (en) * 1996-10-29 1998-05-07 Thomas Spies Cell stress regulated human mhc class i gene
WO1998033891A1 (en) * 1997-01-31 1998-08-06 Hemosol Inc. Method for the production of selected lymphocytes
WO1999046365A1 (en) 1998-03-12 1999-09-16 Emory University Methods and compositions for the selective expansion of gamma/delta t-cells

Also Published As

Publication number Publication date
WO2000026347A1 (en) 2000-05-11
DE69940352D1 (de) 2009-03-12
CA2349629A1 (en) 2000-05-11
AU1021900A (en) 2000-05-22
AU759373B2 (en) 2003-04-10
ES2319942T3 (es) 2009-05-14
EP1127107B1 (en) 2009-01-21
US6537812B1 (en) 2003-03-25
NZ511760A (en) 2003-10-31
ATE421573T1 (de) 2009-02-15
CA2349629C (en) 2010-01-26
JP2002528115A (ja) 2002-09-03
EP1127107A1 (en) 2001-08-29

Similar Documents

Publication Publication Date Title
EP0726941B1 (en) Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl
EP3369812B1 (en) Generation of antigen specific t cells
US20250283040A1 (en) Methods to Expand a T Regulatory Cell Master Cell Bank
JP2017200486A (ja) 樹状細胞／腫瘍細胞融合物および抗ｃｄ３／ｃｄ２８を使用する抗腫瘍免疫の刺激
JP2004512030A (ja) 特異的細胞溶解性ｔ細胞応答を誘導するための組成物および方法
US20030134415A1 (en) Th1 cell adoptive immunotherapy
EP0966523A1 (en) Method for the production of selected lymphocytes
JP4435985B2 (ja) ＴｃＲγδＴ細胞の生産方法
US20030134341A1 (en) Th1 cell adoptive immunotherapy
CN102112491A (zh) 抗-cd8抗体阻断细胞毒素效应物的引发并导致调节性cd8+t细胞的产生
Toujas et al. Human monocyte‐derived macrophages and dendritic cells are comparably effective in vitro in presenting HLA class I‐restricted exogenous peptides
US20040197903A1 (en) Method for induction of proliferation of natural killer cells by dendritic cells cultured with GM-CSF and IL-15
US7273753B2 (en) Purification and uses of dendritic cells and monocytes
JP4982645B2 (ja) ＴｃＲガンマデルタＴ細胞の産生
US20030194395A1 (en) Th1 cell adoptive immunotherapy
AU2001248162A1 (en) Production of TcR gamma delta T cells
US20030157060A1 (en) Production of tcr gamma delta t cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091006

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091102

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091125

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20091225

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130108

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130108

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees